JSH-23 (Synonyms: NFκB Activation Inhibitor II)

Cell lines

Normal human lung epithelial cell line BEAS-2B and human lung cancer cell line A549

Preparation Method

Cells were treated with different concentrations of NF-κB inhibitor JSH-23 (5, 10, 20, 30, 40, and 50 µM, respectively) for 24 h.

Reaction Conditions

5, 10, 20, 30, 40, and 50 µM for 24 hours

Applications

With the increase in JSH-23 concentration, the inhibition rate for cell viability was gradually increased, and significant differences existed when the JSH-23 concentration was greater than 20 µM.

Animal models

Male 12-week-old normotensive Wistar rats and Prague hereditary hypertriglyceridemic (HTG) rats

Preparation Method

Mice were given a total dose of either 20 mg/kg of JSH-23 (10 mg/kg 8 h prior to cisplatin injection and 5 mg/kg on days 1 and 2 after cisplatin injection) or a total dose of 40 mg/kg body weight of JSH-23 (20 mg/kg 8 h prior to cisplatin injection and 20 mg/kg on day 1 after cisplatin injection) or vehicle (DMSO).

Dosage form

Intraperitoneal injection, 5, 10, 20 mg/kg

Applications

JSH-23 (total dose of 40 mg/kg) resulted in a significant decrease in BUN, serum creatinine and serum NGAL. NGAL is an early diagnostic biomarker of cisplatin-induced AKI. JSH-23 had no effect on BUN and serum creatinine in vehicle-treated mice (Fig. 2).

References:

[1]: Huang L, Li F, Deng P, et al. MicroRNA-223 promotes tumor progression in lung cancer A549 cells via activation of the NF-κB signaling pathway[J]. Oncology research, 2016, 24(6): 405.
[2]: Ozkok A, Ravichandran K, Wang Q, et al. NF-κB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI)[J]. Toxicology letters, 2016, 240(1): 105-113.